Powered by great science

We are utilizing our deep knowledge of drug mechanisms to develop medicines with the potential to provide meaningful differences for people living with psychiatric and neurological conditions.


Our extensive knowledge of how drugs work in the central nervous system fuels our drug discovery and clinical efforts, as we work towards our goal of developing transformative medicines. Our intimate understanding of the biology of muscarinic receptors has propelled our research toward finding novel mechanisms for treating diseases through appropriate activation of the cholinergic system, starting with our lead candidate KarXT.

Product Candidate Indication
Phase 1
Phase 2
Phase 3
M1-M4 muscarinic agonist
Schizophrenia (adjunctive)
Psychosis in adults with inadequate response to standard of care
Negative & Cognitive Symptoms*
Psychosis in Alzheimer's Disease
Muscarinic-targeted drug candidate
Muscarinic-targeted drug candidate
Muscarinic-targeted drug candidate
Target-agnostic drug candidate^
*Planning stage
^In collaboration with PsychoGenics


We are building a portfolio of differentiated therapies led by KarXT, an M1/M4-preferring muscarinic agonist, which has the potential to offer a unique and mechanistically differentiated treatment option for schizophrenia and psychosis in Alzheimer's disease.
Dive Deeper

Clinical trials

Learn more about our clinical trials and review eligibility criteria.
Visit Clinicaltrials.gov

Partnerships & collaborations

We are interested in partnering and collaborating with organizations that share our mission of bringing new treatment options to people living psychiatric and neurological conditions worldwide.
Learn More

Scientific & medical research

Antipsychotic Efficacy of KarXT (Xanomeline−Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study
J Clin Psychiatry 2022; 83(3):21m14316
Weiden, P., Breier, A., et al.
Characterizing the Antipsychotic Activity and Safety Profile of the Novel Muscarinic Agonist KarXT (Xanomeline + Trospium ): Primary and Secondary Results from a Phase 2 Placebo Controlled Trial in Schizophrenia [Poster #W47].
2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; 2021 June 1-4.
Sauder, C., Brannan, S.K., et al.
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
N Engl J Med 2021; 384:717-726
Brannan, S.K., Sawchak, S., et al.
Xanomeline’s Activity in Rodent Models of Psychosis: Role of Central Muscarinic Receptors and Augmentation by Risperidone and Aripiprazole [Poster #T42].
2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; 2021 June 1-4.
McKinzie, D., Fischer, K., et al.
Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
ACS Chemical Neuroscience 2019 10 (3), 1753-1764.
Thorn, C., Moon, J., et al.
Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.
Schizophrenia Research 2000; 42: 249–259.
Shannon, H.E., Rasmussen, K., et al.